Hemrajani Rekha
- SEC CIK
- 0001771213
No open-market purchases or sales filed in the past year.
Current role at each company
- MXCT Maxcyte, Inc.Directoras of Jun 22, 2026
- BIOA BioAge Labs, Inc.Directoras of Jun 12, 2026
- LBRX LB Pharmaceuticals IncDirectoras of Jun 5, 2026
- ALXO Alx Oncology Holdings IncDirectoras of Jan 21, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Hemrajani Rekha as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MXCT Maxcyte, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2025 (view filing) | Jun 25 | 63 daysLate | Hemrajani RekhaDirector | SSale | −10.7K | $2.09 | −$22.3K | −21.1%39.9K after | 10b5-1 |
BIOA BioAge Labs, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2025 (view filing) | Sep 27, 2024 | 164 days | Hemrajani RekhaDirector | PPurchase | +3.00K | $18.00 | +$54.0K | New position3.00K after | Amended |
ALXO Alx Oncology Holdings Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2024 (view filing) | Dec 2 | 2 days | Hemrajani RekhaDirector | PPurchase | +30.0K | $1.55 | +$46.5K | +1,000.0%33.0K after |